Akums Drugs Opens at ₹725, Climbing 6.8% in Tepid Market DebutAkums Drugs Opens at ₹725, Climbing 6.8% in Tepid Market Debut

Akums Drugs’ share price had a tepid start today, opening at ₹725 on both NSE and BSE, marking a 6.8% increase from its issue price of ₹679. The stock’s debut showed modest investor enthusiasm.

Akums Drugs and Pharmaceuticals Ltd.’s IPO saw substantial interest, especially on the final bidding day, with a 63.44x overall subscription. QIBs led at 90.09x, non-institutional investors at 42.10x, retail at 20.80x, and the employee segment at 4.14x. 

Akums Drugs and Pharmaceuticals Limited Established in 2004, is India’s top CDMO by revenue, capacity, and client base, holding a 30.2% market share in 2024. They produce 4,146 formulations in 60 dosage forms across ten manufacturing sites with global accreditations. Notable for strong ties with clients like Alembic Pharmaceuticals and Cipla, they boast a high repeat order rate.

Akums Drugs aims to use IPO proceeds to repay debts, boost working capital, fund acquisitions for growth, and cover general corporate expenses to enhance operations and market presence.